Biotech Spotlight


  • brain on purple AI
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders

    Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.

    By July 15, 2024
  • Lovisa Afzelius, co-founder, CEO, Prologue Medicines
    Image attribution tooltip
    Permission granted by Prologue Medicines
    Image attribution tooltip
    Biotech Spotlight

    Protein power: a biotech mining viruses to fight disease

    Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.

    By Kelly Bilodeau • July 1, 2024
  • FibroBiologics CEO Pete O'Heeron at the opening bell for the Nasdaq
    Image attribution tooltip
    Permission granted by FibroBiologics
    Image attribution tooltip
    Biotech Spotlight

    Regenerative cell therapy biotech uses IPO to blast into human trials

    Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

    By June 5, 2024
  • 3d rendering of Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges

    By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.

    By Alexandra Pecci • May 30, 2024
  • Shankar Musunuri
    Image attribution tooltip
    Permission granted by Ocugen
    Image attribution tooltip
    Biotech Spotlight

    Traditional gene therapies are uber-niche. Ocugen hopes to change that.

    The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.

    By Alexandra Pecci • April 15, 2024
  • MRI Brain Axial Glioblastoma
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    What’s old is new: The revival of a one-time radiotherapy cancer treatment

    TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.

    By April 10, 2024
  • shingles vaccine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

    Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

    By Alexandra Pecci • March 19, 2024
  • lots of colorful pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Black Diamond looks to outwit cancer mutations

    Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.

    By Kelly Bilodeau • March 4, 2024
  • Caroline Loew, chief executive officer of Mural Oncology
    Image attribution tooltip
    Permission granted by Mural Oncology
    Image attribution tooltip
    Q&A

    Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

    With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

    By Alexandra Pecci • Feb. 6, 2024
  • 4D Molecular Therapeutics CEO David Kirn
    Image attribution tooltip
    Permission granted by 4DMT
    Image attribution tooltip
    Q&A // Biotech Spotlight

    One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery

    4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.

    By Jan. 10, 2024
  • Gene editing
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

    Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

    By Dec. 19, 2023
  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

    By Nov. 15, 2023
  • Sarah Boyce, CEO and president, Avidity Biosciences
    Image attribution tooltip
    Permission granted by Avidity
    Image attribution tooltip
    Biotech Spotlight

    A new delivery method muscling its way into the RNA space

    With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

    By Kelly Bilodeau • Nov. 8, 2023
  • vaccine ampoules on red
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Cidara’s J&J-partnered immunotherapy could target flu and cancer

    On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

    By Alexandra Pecci • Oct. 26, 2023
  • Antibodies autoimmune disease
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    An ‘inverse vaccine’ takes aim at autoimmune diseases

    Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

    By Kelly Bilodeau • Oct. 23, 2023
  • pediatric cancer concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    To close the pediatric innovation gap, this biotech has to think differently

    Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

    By Alexandra Pecci • Oct. 11, 2023
  • dna tube
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    A biotech ‘tuning’ the genome for a potentially safer gene therapy

    Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

    By Kelly Bilodeau • Oct. 9, 2023
  • highway
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Immuneering takes aim at cancer’s ‘superhighway’

    After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

    By Kelly Bilodeau • Sept. 11, 2023
  • Test tube blood
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    ‘We need to do better:’ A biotech CEO on standing apart from the crowd

    The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

    By Aug. 29, 2023
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Brii Biosciences aims to come up big where Sage and Biogen fell short

    The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

    By Kelly Bilodeau • Aug. 21, 2023
  • Michael Severino, CEO, Tessera Therapeutics
    Image attribution tooltip
    Permission granted by Tessera
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Why AbbVie’s former president has high hopes for this Flagship-backed biotech

    The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

    By Karissa Waddick • Aug. 7, 2023
  • Liver model
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    How CymaBay overcame a NASH failure for another shot at liver disease success

    The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

    By Aug. 2, 2023
  • Aerial view of Shanghai at night
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Zai Lab looks to expand beyond China and make a global impact in oncology

    Focused on making a “transformational” impact, the company is developing targeted treatments driven by specific cancer mutations.

    By Kelly Bilodeau • June 12, 2023
  • Bahija Jallal Immunocore 2
    Image attribution tooltip
    Permission granted by Bahija Jallal
    Image attribution tooltip
    Q&A // Biotech Spotlight

    How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

    The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

    By May 5, 2023
  • Pills of varying colors lay on top a map of the human brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Emalex aims at a first-in-class breakthrough for Tourette syndrome

    With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

    By Kelly Bilodeau • May 1, 2023